Clinical Trial Document Verification in Australia: TGA, HREC and ICH E6 Requirements

Clinical trial document verification in Australia refers to the systematic process of confirming that all essential documents required by Good Clinical Practice (GCP) guidelines — including protocols, consent forms, investigator files and the Trial Master File — are complete, accurate and retained in accordance with applicable Australian regulations. The principal regulatory authority is the Therapeutic Goods Administration (TGA), operating under the Therapeutic Goods Act 1989, with ICH E6(R2) GCP guidelines adopted as the applicable standard for drug trials. Human Research Ethics Committees (HRECs) provide ethical oversight under the National Statement on Ethical Conduct in Human Research (National Statement 2007, updated 2018), published by the National Health and Medical Research Council (NHMRC). Inadequate trial documentation is among the most frequently cited findings in TGA GCP inspections and can result in data invalidation, suspension of a clinical trial, or refusal of a subsequent marketing authorisation application.

This article is for informational purposes only and does not constitute legal or regulatory advice. Regulatory references are accurate as of the publication date.

Essential Documents in Australian Clinical Trials: ICH E6 and TGA Requirements

ICH E6(R2) Section 8 — adopted by the TGA as the applicable GCP standard — defines essential documents as those that individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced, and must be present in both the sponsor's and investigator's files.

These documents fall into three temporal categories: those generated before the trial begins, during the conduct period, and after trial completion or termination. The TGA's GCP guidance documents specify Australian-specific expectations for document content, format and retention, with particular reference to the CTN and CTA schemes that are unique to the Australian regulatory system.

ICH E6(R2), adopted in 2016 and currently being updated under ICH E6(R3), introduced a risk-based approach to monitoring that fundamentally changes how documents are generated, verified and maintained, shifting emphasis from routine on-site visits to centralised, data-driven oversight. The TGA has indicated its intention to align with ICH E6(R3) as it is finalised.

For broader context on regulatory documentation requirements across the life sciences, see our article on pharmaceutical compliance and GxP requirements.

TGA Regulatory Framework: CTN Scheme and the Therapeutic Goods Act 1989

Clinical trials of unapproved therapeutic goods in Australia are regulated under the Therapeutic Goods Act 1989, primarily through two regulatory pathways: the Clinical Trial Notification (CTN) scheme and the Clinical Trial Approval (CTA) scheme. The CTN scheme is by far the more commonly used pathway for drug trials in Australia and represents one of the most streamlined clinical trial regulatory entry points among developed regulatory jurisdictions.

CTN scheme (Clinical Trial Notification)

Under the CTN scheme, the sponsor notifies the TGA of the intended trial — the TGA does not evaluate the trial before it commences. The institutional HREC at each participating site is responsible for evaluating the scientific validity and ethical acceptability of the trial, including the merit and safety of the investigational product. The TGA receives the notification and registers it, but the 14-day notification process does not require TGA scientific review or approval before the trial begins. This places significant responsibility on the HREC to assess product safety data (including the Investigator's Brochure).

CTA scheme (Clinical Trial Approval)

The CTA scheme requires the TGA to evaluate the trial before it commences. This pathway is typically used where the HREC declines to accept full responsibility for evaluating the scientific and safety aspects of the investigational product, or where the sponsor seeks TGA regulatory engagement during the design phase. The CTA involves a more substantive TGA review process with associated fees and timelines.

Key sponsor responsibilities under both pathways, as specified in the TGA GCP guidance, include:

• Establishing and maintaining the TMF in a condition accessible to TGA inspectors at any time during and after the trial
• Reporting adverse events to the TGA in accordance with the requirements of the Therapeutic Goods (Medical Devices) Regulations 2002 and the associated guidance for drug trials
• Submitting substantial protocol amendments to the TGA and obtaining updated HREC approval before implementing changes at site
• Ensuring that all participating institutions have current HREC approval from a recognised HREC prior to participant enrolment

The TGA conducts GCP inspections of sponsors, CROs and investigator sites as part of its compliance monitoring programme. Australia is a member of the International Coalition of Medicines Regulatory Authorities (ICMRA) and participates in mutual recognition arrangements for GCP inspection information sharing with international regulators including the EMA, FDA and Health Canada.

Multi-state trial set-up adds complexity for Australian sponsors. While the National Mutual Acceptance (NMA) scheme enables a single ethics review at a lead HREC to be accepted by participating sites across most Australian states and territories, individual institutions may require additional local governance authorisation, and state-based health department requirements can impose additional documentation obligations. Sponsors must map the ethics and governance landscape for each site and maintain accurate records of all approvals.

HREC Requirements: Ethics Documentation and the National Statement

In Australia, Human Research Ethics Committees (HRECs) provide independent ethical oversight of clinical research involving humans, operating under the National Statement on Ethical Conduct in Human Research (National Statement 2007, updated 2018), a joint publication of the NHMRC, the Australian Research Council (ARC) and Universities Australia.

The National Statement establishes minimum requirements for HREC composition, review processes, informed consent, privacy protection and the ethical conduct of research. Key National Statement requirements with direct documentation implications include:

• HREC composition: A recognised HREC must have a minimum of eight members including lay people, people with expertise in law, a minister of religion or equivalent, and researchers with relevant scientific expertise. HRECs must maintain records of membership, conflicts of interest, meeting minutes and all review decisions.
• Continuing review: HRECs conduct annual or more frequent review of approved research. Sponsors must hold and document current HREC approval for the full duration of the trial; lapsed approval is a significant TGA inspection finding.
• Trial registration: Clinical trials conducted in Australia must be registered in a publicly accessible registry before recruiting participants. The Australian New Zealand Clinical Trials Registry (ANZCTR) is the primary national registry; registration in ClinicalTrials.gov is also accepted. The registration number must appear in participant-facing documents and in the TMF.
• Substantial amendments: Any change to the protocol, consent form or participant-facing materials that may affect participant welfare or the scientific validity of the trial requires a substantial amendment submission to the HREC, with written approval before implementation.

Under the NMA scheme, a single ethics review by a lead HREC can be accepted by participating institutions without local HREC review, subject to local governance authorisation. Sponsors must retain the lead HREC approval together with each participating institution's local governance authorisation in the TMF's site-specific files. The NMA scheme does not remove the requirement for local governance authorisation, and sponsors must not conflate ethics approval with site activation.

Trial Master File and Data Privacy: Privacy Act 1988 and Australian Requirements

The Trial Master File in Australian clinical trials must be maintained in accordance with ICH E6(R2) Section 8 and TGA GCP guidance. The eTMF is now the industry standard for commercial drug development programmes, offering simultaneous multi-user access, role-based access controls, automated audit trails and real-time completeness metrics.

The DIA TMF Reference Model provides a widely adopted framework for eTMF organisation. For Australian trials, Zone 03 (Regulatory and Ethics) must include TGA CTN notifications or CTA approvals together with HREC approval letters and ANZCTR registration confirmation. Zone 04 (Sites) must include site-specific HREC approvals and local governance authorisations for each participating institution.

Data privacy for clinical trial participant records in Australia is governed by the Privacy Act 1988 (Cth) and the Australian Privacy Principles (APPs), administered by the Office of the Australian Information Commissioner (OAIC). The APPs apply to private-sector organisations with an annual turnover of more than $3 million and to health service providers of any size — the latter threshold capturing clinical trial sites and hospital-based research units. Key APP obligations relevant to clinical trial sponsors include:

• APP 3 (Collection of solicited personal information): personal information, including participant health data, may only be collected if directly related to the organisation's activities and if the individual has consented or another lawful basis applies.
• APP 5 (Notification of the collection of personal information): participants must be notified at the time of or before collection of the purposes of collection — typically addressed through the informed consent process.
• APP 11 (Security of personal information): sponsors and CROs must take reasonable steps to protect participant information from misuse, interference, loss, and unauthorised access. This extends to TMF systems holding identifiable participant data.
• APP 8 (Cross-border disclosure): where participant data is transferred to overseas parties (including global sponsors, CROs or eTMF providers with offshore infrastructure), sponsors must take reasonable steps to ensure the recipient meets standards comparable to the APPs.

State-based privacy laws apply in some circumstances, particularly where public hospitals and state health authorities are acting as investigator sites. The OAIC publishes guidance on the interaction between the Privacy Act 1988 and health research, and Australian clinical trial sponsors should review this guidance when designing their data management plans.

Document retention under Australian regulatory requirements: TGA guidance specifies that essential trial documents must be retained for a minimum of 15 years after the completion or termination of the trial, or longer if required by applicable state law or contractual obligations. For multi-regional trials involving the EU, the 25-year EU standard is commonly applied to align with CTR 536/2014 Article 58.

Automating Clinical Trial Document Verification in Australia

Automated clinical trial document verification enables sponsors and CROs to detect TMF gaps in real time, validate document completeness against ICH E6(R2) Section 8 requirements and TGA GCP inspection criteria, and maintain continuous compliance readiness rather than undertaking reactive remediation before an inspection.

Australian clinical trials generate substantial document volumes per site per study period, produced by multiple parties across multiple states and, in multi-regional studies, multiple jurisdictions. Manual verification of this volume is costly, error-prone and structurally incompatible with the timeframes TGA GCP inspectors apply for TMF access during an inspection — typically 24 to 72 hours notice.

CheckFile addresses these challenges through several core capabilities:

• Automatic extraction and classification: identification and categorisation of documents by content type (protocols, amendments, consent forms, investigator CVs, HREC approval letters, TGA CTN notifications, ANZCTR registration confirmations) with 98.7% OCR accuracy, enabling reliable indexing even for scanned or lower-resolution documents received from investigator sites.
• TMF completeness checking: automated verification of the presence of each required artefact against the DIA TMF Reference Model taxonomy, with a real-time gap report available to TMF managers and quality assurance teams. For Australian trials, this includes verification of site-specific governance authorisations alongside HREC approvals.
• Date and signature validation: detection of unsigned documents, inconsistent dates, lapsed HREC approvals, superseded consent form versions still in active use, and missing TGA notification confirmations — before these issues become inspection findings.
• API integration with existing eTMF platforms: connection via API to major eTMF systems to trigger verification checks automatically upon document receipt and filing.

Our platform has processed over 2.4 million verified documents, giving us a robust benchmark dataset for completeness and consistency checks across regulated-sector document types. This translates to an 83% reduction in document processing time compared to manual verification workflows, freeing clinical data management teams to focus on higher-value activities such as data query resolution and site management.

For information on our verification solutions for regulated industries, visit our platform overview. For related coverage on credential verification in the healthcare sector, see our article on healthcare credential verification and accreditation.

The security of clinical trial data is a fundamental requirement under the Australian regulatory framework: participant data is protected by the Privacy Act 1988 and the APPs, and health service providers are subject to heightened obligations for sensitive health information. CheckFile processes documents within a security architecture meeting ISO 27001 standards and compliant with Australian privacy requirements.

Frequently Asked Questions

What is the difference between the CTN scheme and the CTA scheme in Australia?

The Clinical Trial Notification (CTN) scheme is a 14-day notification process under which the TGA registers the trial without evaluating the investigational product before it commences — the HREC at each participating site assumes responsibility for assessing product safety and scientific validity. The Clinical Trial Approval (CTA) scheme requires affirmative TGA evaluation and approval before the trial begins, involving a more substantive review process with associated fees and timelines. Most commercial drug trials in Australia use the CTN scheme. The CTA scheme is used where sponsors seek a higher level of regulatory engagement, or where an HREC declines to accept full responsibility for evaluating the product's non-clinical and clinical safety profile.

What HREC documentation must be retained in the Australian TMF?

The sponsor must retain copies of all HREC approval letters covering the full period of the trial, including any annual renewals and letters approving substantial amendments to the protocol, consent form or site personnel. For multi-site trials under the NMA scheme, the sponsor must retain the lead HREC approval together with each participating institution's local governance authorisation. ANZCTR registration confirmation must also be filed in the TMF, as registration is a mandatory condition for conducting a clinical trial in Australia. Lapsed HREC approval — where the trial continued beyond the approval period without renewal — is a significant TGA GCP inspection finding.

How does the Privacy Act 1988 apply to clinical trial participant data?

The Privacy Act 1988 and the Australian Privacy Principles (APPs) apply to health service providers (including clinical trial investigator sites operating as health service providers) regardless of size, and to private-sector organisations with an annual turnover exceeding $3 million. Clinical trial sponsors and CROs operating in Australia must ensure that participant data is collected with appropriate consent, used only for identified purposes, protected by proportionate security measures, and not disclosed to overseas recipients without taking steps to ensure comparable privacy protections. The informed consent process must address these obligations clearly and in plain language accessible to participants.

What triggers a TGA GCP inspection and how should sponsors prepare?

The TGA selects trials for GCP inspection based on risk criteria including product type, development phase, therapeutic area, and sponsor compliance history. Inspections may be triggered by a regulatory submission (e.g., an Australian Register of Therapeutic Goods application), a safety signal, or as part of a surveillance programme. Preparation centres on three areas: TMF completeness (all ICH E6(R2) Section 8 documents present, including TGA notifications, HREC approvals, and ANZCTR registration), staff training records (delegation logs, GCP training certificates), and internal audit evidence demonstrating that compliance gaps have been proactively identified and remediated.

Does a sponsor need to report adverse events to both the TGA and the HREC?

Yes. Australian sponsors have parallel reporting obligations. Serious unexpected adverse reactions (SUSARs) must be reported to the TGA within specified timeframes under TGA adverse event reporting requirements. The same SUSARs must also be reported to the HREC in accordance with the HREC's reporting requirements, which may specify different timelines or formats. Line listings of SUSARs must be submitted to the HREC at least annually. The TMF must contain evidence of both TGA and HREC adverse event reports and the associated acknowledgements. Failure to report SUSARs to either authority is a Critical finding in a TGA GCP inspection.

Find out how CheckFile supports clinical trial sponsors with automated document verification in Australia, or explore our pricing to find the right plan for your document volume. For a broader view of verification requirements across regulated sectors, see our industry verification guide.